FDA grants accelerated approval for Bristol Myers Squibb’s Augtyro for NTRK-positive tumors
Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene ... Read More
Novartis reveals significant results for Fabhalta in IgAN study at World Congress of Nephrology
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in proteinuria in a pivotal Phase III trial. ... Read More
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted ... Read More